Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 68

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 68
---
 potentially to treat or
cure serious infectious diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infections. As a result of our
acquisition of GEDi Cube on February 13, 2024, we have also expanded our technology pipeline to include diagnostic related services with
an early emphasis on the detection of cancer.

Our Product
Development strategy related to our allogeneic cell and gene therapies is anchored in the use of “non-self” or allogeneic
cells that enhance the immune response that we seek to elicit.

Over the past several years, Renovaro
Biosciences has evolved from a company with a single product candidate as a potential cure for HIV (RENB-HV12 and RENB-HV21), a pipeline
for Hepatitis B Virus (HBV) (RENB-HB01), and with a significant expansion into cancer immune therapies to address high unmet needs from
difficult-to-treat solid tumors (RENB-DC11.)

The oncology platform is now at
the forefront of our development activities, beginning with pancreatic cancer and other solid tumors with poor life expectancy, such as
triple negative breast, second-line liver, head, neck, and oral among other possible targets.

Many operational aspects of our
platforms can be quickly adapted to multiple disease states from a single therapeutic approach, potentially streamlining and accelerating
development, and regulatory process, as well as manufacturing operations. Moreover, because our product candidates do not require specialized
delivery devices and surgical procedures, our potentially groundbreaking interventions could have worldwide applicability.

Renovaro Biosciences responds quickly
to new data and perceived development opportunities and risk assessments. Based on the maturation of our pipelines, the Company makes
business decisions to prioritize the programs that could move more rapidly through development and commercial processes.

<div align='center'>36</div>

Therapeutic Platforms

Renovaro Bioscience’s general
approach with gene- and/or cell-therapy is to train the immune system to allow a person to better fight diseases. Our vision is for a
world free from toxic chemotherapy and healthy longevity for those with cancer and other diseases. Renovaro Biosciences is leveraging
general principles and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote the recognition
and elimination of diseased cells.

Advanced Allogeneic Cell Therapy

The strategic benefit of cell therapy
platforms is to potentially